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Open access under the Elsa b s t r a c t
Haplotypes formed by clinically relevant polymorphisms in the endothelial nitric oxide synthase (eNOS)
gene have been associated with variations in endogenous nitric oxide (NO) formation in white and black
subjects. We examined whether further genetic variation and haplotypes of the eNOS gene, represented
by the rs3918188, rs743506 and rs7830 tagSNPs (polymorphisms that represent the information of
neighboring SNPs in linkage disequilibrium) affect endogenous NO formation in 181 healthy black sub-
jects. We measured whole blood nitrite concentration as a marker of endogenous NO formation for each
subject. We found that the heterozygotes CA for the tagSNP rs7830 (P = 0.0278, OR = 0.4839, CI 95%
0.2567–0.9121), as well as the haplotype ‘‘C–G–A’’ (P = 0.0068), were more common in subjects with
low circulating whole blood nitrite concentrations compared with subjects with high circulating whole
blood nitrite concentrations, although the genotype ﬁnding is not signiﬁcant after correction for multiple
comparisons. These ﬁndings suggest that these tagSNPs of the eNOS gene and haplotypes are associated
with low levels of nitric oxide production in blacks, and could be used as a marker of cardiovascular risk.
 2012 Elsevier Inc. Open access under the Elsevier OA license. Introduction
Nitric oxide (NO) is a biological signaling molecule that plays a
critical role in vascular homeostasis [1]. NO is synthesized from L-
arginine and oxygen by three different isoforms of the enzyme NO
synthase (NOS) including neuronal NOS (nNOS or NOS1), inducible
NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3), which
present different tissue pattern distribution but with some overlap
[2,3]. nNOS is involved in many functions including central ner-
vous system regulation of blood pressure, smooth muscle relaxa-
tion [4–6], and also contributes to vasorelaxation, especially
when eNOS is malfunctional [2,7]. Recently an association between
nNOS single nucleotide polymorphisms (SNPs) and susceptibility
to stroke development has been shown [8]. iNOS has an important
role in the pathophysiology of inﬂammatory diseases, septic shock,
and may also contribute to the pathogenesis of hypertension
[2,9,10]. Fu et al. (2009) found an association between iNOS SNP
1026C/A and hypertension under inﬂammatory conditions [11].
Morevover, the iNOS gene polymorphism (CCTTT)n together with
eNOS SNP Glu298Asp were associated with coronary heart disease
and severity of chronic heart failure [12]. However, under physio-f Pharmacology, Faculty of
lo, Av. Bandeirantes 3900,
2 0220.
s@yahoo.com (J. E. Tanus-
evier OA license. logical conditions, NO is mainly synthesized from L-arginine and
oxygen by eNOS in the endothelial cells [13]. This enzyme is
responsible for blood vessels dilatation, blood pressure control,
and other vasoprotective and anti-atherogenic actions [2,9].
NO metabolism generates various products [14]. While prod-
ucts of NO oxidation include nitrites and nitrates [14–16], there
is now evidence that nitrites are relevant markers of endogenous
NO production by vascular and cardiac cells [15,17,18] and reﬂect
constitutive NOS activity more precisely than nitrates levels
[15,16,19–21]. Moreover, two thirds of intravascular nitrites are
usually located within red blood cells, and therefore the measure-
ment of whole blood nitrites concentrations are more relevant to
study endogenous nitric oxide production [22,23].
Interethnic differences in vascular reactivity [24,25] and in NOx
(nitrate + nitrite) levels [26,27] were shown, and it clear that black
Americans have higher prevalence and severity of hypertension
than white Americans [28,29]. However, these interethnic differ-
ences in disease prevalence may reﬂect interethnic differences in
allele frequencies, and consequently haplotypes distributions
[30]. This is clearly the case of eNOS gene, and signiﬁcant intereth-
nic differences in the distribution of eNOS genotypes and haplo-
types have been consistently described in different populations
[31–33].
Three clinically relevant polymorphisms in the eNOS gene have
been widely studied because they may affect NO production: the T-
786C (rs2070744), which is a single nucleotide polymorphism
(SNP) in the promoter region, a 27 bp variable number of tandem
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7 [34]. Previous studies have examined the effects of these eNOS
polymorphisms on the endogenous NO formation in white
[35,36] and black subjects [37]. Other polymorphisms have been
studied with the idea of addressing a broader range of genetic var-
iability in this gene. Indeed, the tagSNPs rs3918188, rs743506 and
rs7830 have also been studied in regard to endothelial function
[38–40], and recently another SNP, the rs3918226, was associated
with hypertension in two large GWAS studies focused on gene-
centric arrays [41,42]. However, this last polymorphism was not
associated with altered levels of nitrite in healthy subjects [43].
The recent ﬁndings of the GWAS studies [41,42] clearly show that
the genetic variability in eNOS gene has not been fully explored
and it is possible that other polymorphisms, which may be in link-
age disequilibrium with tagSNPs, exert some inﬂuence on eNOS
enzyme or on its products.
The objective of the present study was to examine whether
these three eNOS tagSNPs (rs3918188, rs743506 and rs7830), or
the haplotypes formed by them, could affect NO formation in
healthy black subjects.Materials and methods
Subjects
This study was approved by the Institutional Review Board at
the Hospital São Rafael-Salvador-BA, and each subject provided
written informed consent. The present work was carried out in
accordance with the ethics standards of the Helsinki Declaration.
We studied 181 healthy male volunteers (age range: 18–63 years)
who were nonsmokers, recruited from Salvador (BA, Brazil), and
self-reported as blacks. Because the Brazilian population is hetero-
geneous, we have not studied subjects self-reported as intermedi-
ate. Arterial blood pressure and heart rate were measured with a
sphygmomanometer (HEM-433INT, Omron Healthcare, Inc, Ban-
nockburn, IL, USA) three times after at least 15 min of rest. Venous
blood samples were collected after the subjects gave after in-
formed consent.
Genomic DNA was extracted from the cellular component of
1 mL of whole blood by a salting-out method [44] and stored at
20 C until analyzed.Genotypes determination
Three tagging SNPs, rs3918188, rs743506 and rs7830 were se-
lected from the Genome Variation Server-GVS of SeattleSNPs
(http://gvs.gs.washington.edu/GVS/) using the parameters of
r2P 0.8 threshold for clusters of linkage disequilibrium (LD)
among polymorphisms, and minor allele frequency (MAF) P10%.
Importantly, while these three tagSNPs are located in intron 14, in-
tron 20 and in the 30 untranslated region (UTR), respectively, the
previously studied SNPs rs2070744 and rs1799983 are located in
the promoter region and in the exon 7 of eNOS gene, respectively
(22). Therefore, the inclusion of the three tagsSNPs capture a
broader extension and all the ﬁve SNPs together represent, respec-
tively, 37.1% and 51.5% of the common genetic variation of eNOS
gene for Europeans and Africans of SeattleSNPs. Genotypes for
rs743506 were determined by Taqman Allele Discrimination assay
and real-time PCR on Chromo 4 Detector (Bio-Rad Laboratories,
USA) [45]. However, genotypes for the rs3918188 and rs7830 were
determined by PCR followed by endonuclease digestion and frag-
ment separation by electrophoresis in 8% polyacrylamide gels as
previously described [46].Measurement of nitrite concentrations in whole blood samples
To measure whole blood nitrite concentrations in triplicate, ve-
nous blood samples were collected into tubes containing heparin
and immediately mixed with a nitrite preservation solution in a
5:1 dilution as previously described [47]. Brieﬂy, this solution con-
tains 0.8 M ferricyanide and 1% NP-40. The samples were deprote-
inated with methanol (1:1) and centrifuged at 14,000g for 5 min.
Then, 200 lL supernatant was injected into the solution of acidiﬁed
tri-iodide, purged with nitrogen in-line with a gas-phase chemilu-
minescence NO analyzer (Model 280, NO analyzer; Sievers Boulder,
CO, USA), as described previously [20]. Approximately 8 mL of tri-
iodide solution (2.0 g of potassium iodide and 1.3 g of iodine dis-
solved in 40 mL of water with 140 mL of acetic acid) were placed
in the purge vessel into which samples were injected. The triiodide
solution reduced nitrites to NO gas, which was detected by the NO
analyzer.
Measurement of thiobarbituric acid-reactive species (TBA-RS) in
plasma
TBA-RS were determined in plasma samples as previously de-
scribed [48] to assess oxidative stress. Brieﬂy, 0.2 ml of sample
was added to the reaction mixture containing 0.5 ml of 1% phos-
phoric acid (pH 2.0), 0.25 ml aqueous solution of 0.6% TBA (ﬁnal
volume of 1.0 ml), followed by 60 min heating at 95 C. After cool-
ing, samples and standards of malondialdehyde were read at
532 nm against the blank of the standard curve.
Haplotype inference
Haplotypes were inferred using the Bayesian statistical based
program PHASE version 2.1 (http://www.stat.washington.edu/ste-
phens/software.html) [49] to estimate the haplotype frequencies
in the population and the two haplotypes for each subject. To fur-
ther conﬁrm these frequencies we have also used the Haplo.stats
software (version 1.4.4, http://cran.r-project.org/web/packages/
haplo.stats/index.html), which computes maximum likelihood
estimates of haplotype probabilities. These results were used to
evaluate the relationship between eNOS haplotypes and nitrite
concentrations in whole blood samples. The possible haplotypes
including genetic variants of three eNOS tagSNPs studied were:
H1(C–A–C), H2(C–A–A), H3(C–G–C), H4(C–G–A), H5(A–A–C),
H6(A–A–A), H7(A–G–C), and H8 (A–G–A). LD among the tagSNPs
of the present study along with the clinically relevant rs2070744
and rs1799983 previously studied [37] was characterized by calcu-
lating D0 and LOD (log of the likelihood odds ratio, a measure of
conﬁdence in the value of D0) for each pair of SNPs using the Hap-
loview software (version 4.2; http://www.broad.mit.edu/mpg/hap-
loview/). Genotype data for Africans and Europeans was obtained
from the GVS SeattleSNPs and LD maps were also evaluated using
Haploview software.
Statistical analysis
The distribution of genotypes for each polymorphism was as-
sessed for deviation from the Hardy–Weinberg equilibrium by
using Fisher’s test (StatView, Cary, NC, USA). To assess potential
relationships between each polymorphism and whole blood nitrite
concentrations, we used the Kruskal–Wallis test followed by the
Dunn’s multiple comparison test. We compared the distribution
of genotypes, alleles, and the estimated haplotypes frequencies in
subjects with the 45 lowest (L group) nitrite concentrations with
those in subjects with the 45 highest (H group) nitrite concentra-
tions measured in whole blood samples by using Fisher’s test. Be-
cause we considered the comparison of the frequencies of seven
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p value <0.0071 (=0.05/7, which would allow seven simultaneous
comparisons with Bonferroni’s correction) was considered signiﬁ-
cant. Otherwise, a P value <0.05 was considered statistically signif-
icant. Normally distributed data were reported as the mean ± S.D.,
whereas non-normally distributed data were reported as the med-
ian and interquartile range.Results
In order to assess how eNOS polymorphisms affect endogenous
NO formation, nitrite concentrations were measured in whole
blood samples from 181 healthy black male subjects. We carried
out an analysis that paralleled a previous analysis in healthy sub-
jects [37] in which we compared the distribution of eNOS geno-
types, alleles, and the estimated haplotypes frequencies in
subjects with the 45 lowest (L group; lowest quartile) nitrite con-
centrations with those in subjects with the 45 highest (H group;
higher quartile) whole blood nitrite concentrations.
Table 1 summarizes clinical and laboratorial characteristics of
the L and H groups. We found no signiﬁcant differences in age,
body mass index, systolic and diastolic arterial blood pressure,
heart rate, and MDA concentrations (Table 1; all P > 0.05).
The distribution of genotypes for the three polymorphisms
studied here showed no deviation from Hardy Weinberg equilib-
rium (all P > 0.05). When the allele and genotype frequencies inTable 1
Clinical and laboratorial characteristics of study groups.
Total (n = 181)
Age (years) 30.7 + 8.8
BMI (kg/m2) 24.7 + 3.4
SAP (mmHg) 118.1 + 9.8
DAP (mmHg) 78.4 + 8.4
HR (bmp) 71.2 + 8.7
MDA (nmol/L) 3.1 + 1.2
Whole blood NO2 (nmol/L) 287.9 (154.9–501.7)
Values are the mean ± S.D. for normally distributed data, or the median (interquartile ran
pressure; DAP = diastolic arterial pressure; HR = heart rate; MDA = thiobarbituric acid-r
signiﬁcant. p values for ‘‘L’’ compared with ‘‘H’’; ⁄p < 0.05.
Table 2
Genotypes and alleles frequencies in the L and H groups.
Genotypes Total (n = 181) L (n = 45) H (n = 45)
rs3918188
CC 0.40 (73) 0.36 (16) 0.40 (18)
CA 0.46 (83) 0.49 (22) 0.44 (20)
AA 0.14 (25) 0.16 (7) 0.16 (7)
rs743506
AA 0.40 (72) 0.38 (17) 0.40 (18)
AG 0.47 (85) 0.53 (24) 0.47 (21)
GG 0.13 (24) 0.09 (4) 0.13 (6)
rs7830
CC 0.30 (54) 0.22 (10) 0.38 (17)
CA 0.58 (105) 0.67 (30) 0.56 (25)
AA 0.12 (22) 0.11 (5) 0.07 (3)
Alleles Total (n = 362) L (n = 90) H (n = 90)
rs3918188
C 0.63 (229) 0.60 (54) 0.62 (56)
A 0.37 (133) 0.40 (36) 0.38 (34)
rs743506
A 0.63 (229) 0.64 (58) 0.63 (57)
G 0.37 (133) 0.36 (32) 0.37 (33)
rs7830
C 0.59 (213) 0.56 (50) 0.66 (59)
A 0.41 (149) 0.44 (40) 0.34 (31)
Statistical analysis: Fisher’s test, ⁄P < 0.05.
P values correspond to P values for the odds ratio.the L and in the H groups were compared, no signiﬁcant differences
were found except for the rs7830. In fact, the CA genotype for this
polymorphismwas found at higher frequency in the L than in the H
group (67% vs. 56%, respectively, Table 2; P = 0.0278 for odds ratio).
However, this ﬁnding is not signiﬁcant after correction for multiple
comparisons. We found no signiﬁcant effects of genotypes on
whole blood nitrite concentrations (Table 3; all P > 0.05).
Seven haplotypes accounted for nearly 98% of all possible hap-
lotype combinations. We found signiﬁcant differences in the over-
all haplotype frequencies when the L and the H groups were
compared (P = 0.0172). Association between speciﬁc haplotypes
and whole blood nitrite levels is shown in Table 4. Because we
compared the frequencies of seven different haplotypes in the
two groups, a corrected P value <0.0071 was considered statisti-
cally signiﬁcant. While the frequencies of six out of seven possible
eNOS haplotypes were not signiﬁcantly different in the L group
compared with the H group (Table 4; P > 0.0071), the haplotype
including the ‘‘C’’, ‘‘G’’, and ‘‘A’’ alleles for the tagSNPs rs3918188,
rs743506 and rs7830, respectively, was more common in the L
group (7.9%) than in H group (0.0%; Table 4; P = 0.0068).
In order to unravel the LD pattern among the common variation
of eNOS gene studied, we compared the D0 and LOD values be-
tween all the SNPs studied in Brazilian blacks with Africans and
Europeans from SeattleSNPs (Fig. 1). Low LD values were observed
between most of the SNPs pairs of eNOS gene for Brazilian blacks,
and Africans and Europeans from SeattleSNPs, except for rs743506L (n = 45) H (n = 45) p
31.4 + 8.6 29.3 + 9.3 NS
24.4 + 3.7 25.5 + 4.2 NS
117.9 + 10.8 118.7 + 9.4 NS
80.0 + 10.4 79.2 + 7.4 NS
73.2 + 8.3 69.8 + 9.9 NS
3.0 + 0.8 3.3 + 1.6 NS
118.7 (87.3–137.2) 615.9 (551.3–846.1) ⁄
ge) for non-normally distributed data. BMI = body mass index; SAP = systolic arterial
eactive species concentrations in plasma measured as malondialdehyde; NS = non


















Nitrite concentrations in whole blood samples grouped by genotypes for each eNOS
polymorphism.
Genotypes (n = 181) Whole blood NO2- p
CC (n = 73) 341.4 + 223.8
rs3918188 CA (n = 83) 343.9 + 261.5 0.8706
AA (n = 25) 430.0 + 391.9
AA (n = 72) 346.3 + 244.0
rs743506 AG (n = 72) 352.7 + 278.5 0.8812
GG (n = 24) 381.6 + 304.5
CC (n = 54) 399.2 + 288.8
rs7830 CA (n = 105) 344.0 + 268.3 0.2912
AA (n = 22) 291.0 + 189.3
Values are: mean + S.D. (nmol/L).
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tagSNPs for the Africans (D0 = 1, LOD = 2.65, r2 = 0.376) and Europe-
ans (D0 = 1, LOD = 2.95, r2 = 0.256) compared to Brazilian blacks
(D0 = 0.53, LOD = 3.64, r2 = 0.114).
Discussion
This is the ﬁrst study to investigate how eNOS tagSNPs
rs3918188, rs743506 and rs7830 and haplotypes affect NO bio-
availability in black subjects. Our ﬁndings show that the frequen-Table 4
Estimated haplotypes frequencies in L and H groups.
Haplotypes H
rs3918188 rs743506 rs7830
H1 C A C 0
H2 C A A 0
H3 C G C 0
H4 C G A 0
H5 A A C 0
H6 A A A 0
H7 A G C 0
We found differences between ‘‘L’’ and ‘‘H’’ groups (Global test qui-square; P = 0.0172).
P values were considered signiﬁcant only when <0.0071 (= 0.05/7, which would allow s
P values correspond to P values for each haplotype versus the other haplotypes.
Brazilian Blacks SeattleSNPs, A
Fig. 1. Linkage disequilibrium (LD) analysis among the eNOS tagSNPs of the present stud
by their dbSNP rs numbers. Numbers within squares indicate the D0 value expressed as a p
squares D0 < 1 with LODP 2, and white squares D0 < 1.0 and LOD < 2.cies of the CA genotype for the rs7830 tagSNP, as well as the ‘‘C–
G–A’’ haplotype, were higher in subjects with low circulating
whole blood nitrite concentrations compared with subjects with
high concentrations, although the genotype result is not signiﬁcant
after correction for multiple comparisons. These ﬁndings are con-
sistent with the idea of that comparing extremes of phenotype dis-
tribution improves our abilities to ﬁnd genetic contributions to
particular phenotypes [36,37,50].
Nitrite has been considered a major storage pool for NO in the
circulation which can be reduced back to NO under certain condi-
tions [51–53]. Low nitrite concentrations may reﬂect impaired NO
formation possibly promoting cardiovascular diseases [21,23]. This
suggestion is supported by previous ﬁndings showing that eNOS
haplotypes may modify endogenous NO formation and promote
hypertension [54].
The effects of common eNOS gene polymorphisms on ﬂowmed-
iated dilation were previously studied, including the tagSNPs
rs3918188, rs743506 and rs7830, and no signiﬁcant effects were
found for these tagSNPs or haplotypes combining their variants
[38,40]. While some studies reported no associations between
these polymorphisms in kidney disease [55] or glaucoma [56],
the GA genotype of the tagSNP rs743506 showed protective effects
and the haplotypes ‘‘C C a Glu G’’ and ‘‘C C b Glu G’ were associated
with aura in migraine patients [45], thus suggesting pathophysio-
logical implications. Moreover, haplotypes formed by the tagSNPs
rs1808593–rs7830 were signiﬁcantly associated with ankle-bra-aplotypes frequencies L H p
.166 0.100 0.152 0.3928
.246 0.267 0.221 0.5110
.174 0.153 0.250 0.1109
.047 0.079 0.000 0.0068
.126 0.231 0.157 0.2842
.095 0.046 0.104 0.2828
.123 0.071 0.097 0.6133
even simultaneous comparisons); Fisher’s test.
fricans SeattleSNPs, Europeans
y along with the previously studied clinically relevant SNPs (22). SNPs are identiﬁed
ercentile. Black squares indicate pairs in strong LD with LOD scores for LDP 2, gray
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hypertensive adults [39]. Together, these ﬁndings suggest that
these tagSNPs may have pathophysiological implications under
particular circumstances.
Our ﬁndings showing a possible effect of the rs7830 tagSNP on
nitrite concentrations suggest that this tagSNP may affect the car-
diovascular risk. This tagSNP is located in the 30 untranslated re-
gion (UTR) of the eNOS gene, which plays an important role in
gene expression and in cardiovascular pathophysiology [57]. Addi-
tionally, the 30-UTR of mRNA has important physiological and
pathological roles in the regulation of mRNA level [58,59]. There-
fore, the rs7830 tagSNP could also affect mRNA regulation.
To our knowledge, there is no functional data showing the ef-
fects of the rs7830 tagSNP on eNOS activity. However, we per-
formed LD analysis in an attempt to correlate this tagSNP with
the clinically relevant rs2070744 and rs1799983 SNPs previously
studied [37]. Although high LD values were observed between
rs743506 and rs7830, no other high LD value was observed be-
tween these tagSNPs and rs2070744 and rs1799983 in black Bra-
zilians. Therefore, the molecular mechanisms explaining how
genotypes for the rs7830 tagSNP or haplotypes may affect eNOS re-
quire further studies. Moreover, high LD values were also observed
between rs743506 and rs7830 for Africans and Europeans. LD pat-
ters are a result of population history, and the recent admixture oc-
curred in the Brazilian blacks may explain the different LD patterns
observed when compared to Africans and Europeans. Therefore,
while there are major populational differences in the distribution
of eNOS polymorphisms and haplotypes [31–33], pairwise LD val-
ues among eNOS polymorphisms should be further explored to
help interpreting association signals including rs7830.
This study has a limitation that requires some comments. The
subjects enrolled in our study were not on a particular diet before
blood sampling. While it is possible that diet affects the circulating
levels of NO metabolites, it has been shown that approximately
70% of the circulating nitrite levels depend on constitutive nitric
oxide synthase activity [60].
In conclusion, our ﬁndings suggest that the tagSNP rs7830 and
the haplotype ‘‘C–G–A’’ are associated with lower nitric oxide pro-
duction in blacks, and these genetic markers may represent mark-
ers of cardiovascular risk.Acknowledgments
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